Andreescu Mihaela
Hematology, Colentina Clinical Hospital, Bucharest, ROU.
Cureus. 2023 Dec 11;15(12):e50318. doi: 10.7759/cureus.50318. eCollection 2023 Dec.
Antibiotic therapy is a cornerstone of modern medicine, yet the development of antibiotic resistance threatens to render these therapies ineffective. The gut microbiota, a complex ecosystem of microorganisms residing in the gastrointestinal tract, plays a critical role in modulating antibiotic efficacy and resistance. This review delves into the intricate relationship between gut microbiota, antibiotic therapy, and resistance and discusses the potential applications of gut microbiota research in guiding personalized antibiotic therapy and resistance mitigation strategies. Recent advancements in metagenomics, metatranscriptomics, and metabolomics have demonstrated the potential for tailored antibiotic regimens that minimize collateral damage to commensal bacteria and reduce the risk of resistance. Adjuvant therapies, such as probiotics, prebiotics, and synbiotics, have shown promise in restoring gut microbial balance and mitigating the adverse effects of antibiotic therapy. We address the challenges associated with this emerging field, including the need for standardized methodologies, ethical considerations, and interdisciplinary collaboration. With continued interdisciplinary collaboration and the implementation of standardized methodologies, gut microbiota research can contribute to the global fight against antibiotic resistance and improve patient outcomes.
抗生素治疗是现代医学的基石,但抗生素耐药性的发展有可能使这些治疗方法失效。肠道微生物群是存在于胃肠道中的一个复杂的微生物生态系统,在调节抗生素疗效和耐药性方面起着关键作用。本综述深入探讨了肠道微生物群、抗生素治疗和耐药性之间的复杂关系,并讨论了肠道微生物群研究在指导个性化抗生素治疗和耐药性缓解策略方面的潜在应用。宏基因组学、宏转录组学和代谢组学的最新进展表明,定制抗生素方案具有潜力,可将对共生细菌的附带损害降至最低,并降低耐药风险。辅助疗法,如益生菌、益生元和合生素,在恢复肠道微生物平衡和减轻抗生素治疗的不良反应方面已显示出前景。我们阐述了与这一新兴领域相关的挑战,包括对标准化方法的需求、伦理考量以及跨学科合作。通过持续的跨学科合作和标准化方法的实施,肠道微生物群研究可以为全球对抗抗生素耐药性的斗争做出贡献,并改善患者的治疗效果。